Business Context and Reporting Period
The provided filing is Aeglea BioTherapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2023, not a filing under the requested Spyre Therapeutics, Inc. name. Aeglea was a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases, primarily pegtarviliase for Classical Homocystinuria and pegzilarginase for Arginase 1 Deficiency. The financial statements are unaudited.
Financial Results and Position
- Revenue: $0.2 million, compared with $1.4 million in the prior-year quarter, primarily from the Immedica development agreement and royalties. The company had no product revenue.
- Operating expenses: $19.0 million, down 26% from $25.8 million. Research and development expense was $13.8 million, down 19%; general and administrative expense was $5.2 million, down 41%.
- Net loss: $18.4 million, or $0.20 per basic and diluted share, compared with a $24.4 million loss, or $0.37 per share, in the prior-year quarter. The improvement in per-share loss also reflects higher weighted-average shares outstanding.
- Margins: Gross margin and operating margin are not meaningful because revenue consisted primarily of development fees and royalties while the company incurred substantial clinical and corporate expenses. Operating loss was $18.8 million.
- Cash flow: Net cash used in operating activities was $17.6 million, compared with $26.3 million in the prior-year quarter. Investing activities provided $17.8 million, primarily from maturities and sales of marketable securities.
- Liquidity: Cash, cash equivalents and restricted cash totaled $36.6 million at March 31, 2023; cash and cash equivalents plus marketable securities and restricted cash totaled approximately $39.8 million. Working capital was $31.7 million.
- Balance sheet: Total assets were $52.5 million and total liabilities were $18.8 million. Accumulated deficit was $444.0 million and stockholders’ equity was $33.7 million.
- Debt and commitments: The company reported no debt or credit facility. Future minimum commitments under its Austin facility lease totaled approximately $5.8 million through April 2028.
- Capital structure: 65.4 million common shares were outstanding at March 31, 2023. In addition, 28.9 million pre-funded warrants were outstanding with a $0.0001 exercise price and no expiration date.
Material Changes Versus the Prior Comparable Period
- Revenue declined by $1.2 million, or 85%, as development-fee revenue under the Immedica agreement decreased from $1.4 million to $0.2 million.
- Research and development expense decreased by $3.2 million, mainly due to lower PEACE Phase 3 trial costs, lower BLA submission expenses and reduced spending on the pegzilarginase Phase 1/2 trial.
- General and administrative expense decreased by $3.6 million, reflecting lower personnel, commercial and financing-related expenses.
- Net loss improved by $6.0 million, or 25%, while operating cash burn decreased by $8.6 million.
- Marketable securities declined from $20.8 million at December 31, 2022 to $3.2 million at March 31, 2023, primarily reflecting maturities and sales used to fund operations.
Guidance, Outlook, Risks and Unusual Items
- In April 2023, after reviewing inconclusive interim results from the pegtarviliase Phase 1/2 trial, management began exploring strategic alternatives, including a merger, acquisition, reverse merger, asset sale or divestiture of clinical programs.
- The company paused additional clinical development and planned to reduce or eliminate clinical, manufacturing and commercial development spending.
- The board approved an approximately 83% workforce reduction, retaining approximately 10 employees. The company estimated approximately $6.2 million of restructuring charges, including $5.6 million of cash costs and $0.6 million of non-cash stock-based compensation, with most charges expected in the second quarter of 2023.
- The company stated that the pegtarviliase interim results supported further dose and duration exploration, but the third cohort did not show a consistent reduction in homocysteine and was affected by anti-drug antibodies. Enrollment was paused for business reasons.
- Pegzilarginase demonstrated positive Phase 3 topline results, but the FDA previously issued a Refusal to File letter requesting additional effectiveness and Chemistry, Manufacturing and Controls information. The European Medicines Agency review remained underway, with a potential decision expected in late 2023.
- Management concluded that substantial doubt existed about the company’s ability to continue as a going concern within twelve months after issuance of the financial statements. The company expected to fund operations through its strategic-alternatives process, but no transaction was assured.
- The principal risks were failure to complete a strategic transaction, potential wind-down or liquidation, inability to raise additional capital, clinical and regulatory failure, workforce and key-person losses, dilution from pre-funded warrants and continued operating losses.
- Cash deposits of approximately $31.8 million exceeded FDIC insurance limits at March 31, 2023. The company also remained exposed to interest-rate and foreign-exchange risks, although management considered those exposures immaterial.
Facts an Investor Should Verify
- Confirm that the intended issuer is Aeglea BioTherapeutics rather than Spyre Therapeutics, because the supplied filing identifies Aeglea and the AGLE ticker.
- Verify the outcome and terms of the strategic-alternatives process, including whether a transaction, asset sale, merger or liquidation occurred.
- Verify actual restructuring charges, cash payments and final employee headcount after the planned second-quarter 2023 reduction.
- Assess the company’s going-concern status, remaining cash runway and any subsequent financing or capital-raising activity.
- Track regulatory developments for pegzilarginase, including the FDA Refusal to File issues and the European regulatory review.
- Review the potential dilution from 28.9 million outstanding pre-funded warrants and any additional equity issued after March 31, 2023.